Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 102,000 | 18,900 | -76,600 | 154,500 | 65,500 |
| Depreciation Amortization | 15,600 | 10,100 | 2,900 | 19,300 | 12,200 |
| Income taxes - deferred | -77,300 | -73,100 | -31,600 | 19,100 | 5,600 |
| Accounts receivable | -67,900 | -37,500 | -41,700 | -162,200 | -115,700 |
| Other Working Capital | 81,900 | 35,900 | -57,500 | -67,400 | -65,900 |
| Other Operating Activity | 212,100 | 100,100 | 79,300 | 376,100 | 294,700 |
| Operating Cash Flow | $266,400 | $54,400 | $-125,200 | $339,400 | $196,400 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -892,700 | -152,700 | -2,300 | -621,200 | -387,900 |
| PPE Investments | -22,900 | -15,300 | -8,500 | -16,500 | -14,700 |
| Net Acquisitions | N/A | N/A | N/A | -42,700 | N/A |
| Purchase Of Investment | -31,300 | N/A | -31,300 | -7,700 | -7,700 |
| Sale Of Investment | 681,600 | N/A | N/A | 511,000 | 348,800 |
| Investing Cash Flow | $-265,300 | $-168,000 | $-42,100 | $-177,100 | $-61,500 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | N/A | -279,000 | -279,000 |
| Common Stock Issued | 29,900 | 11,100 | 8,200 | 44,700 | 20,100 |
| Financing Cash Flow | $29,900 | $11,100 | $8,200 | $-234,300 | $-258,900 |
| Exchange Rate Effect | N/A | N/A | N/A | -1,300 | N/A |
| Beginning Cash Position | 270,700 | 270,700 | 270,700 | 344,000 | 344,000 |
| End Cash Position | 301,700 | 168,200 | 111,600 | 270,700 | 220,000 |
| Net Cash Flow | $31,000 | $-102,500 | $-159,100 | $-73,300 | $-124,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 266,400 | 54,400 | -125,200 | 339,400 | 196,400 |
| Capital Expenditure | -22,900 | -15,300 | -8,500 | -16,500 | -14,700 |
| Free Cash Flow | 243,500 | 39,100 | -133,700 | 322,900 | 181,700 |